Neurogene
Valuation
$93.6M
Funding
$0
Founded
2018
Neurogene revenue, CEO Rachel McMinn, team size, customer count, churn, and more in 2026.
Neurogene is focused on developing life-changing genetic medicines for patients and families affected by rare, devastating neurological diseases.
Last updated
Neurogene Revenue
We do not have information about Neurogene's revenue yet.
Neurogene Valuation, Funding Rounds
Neurogene's most recent disclosed valuation is $93.6M.
Neurogene is a bootstrapped SaaS company, self-funded since its founding in 2018, with no outside investment to date.
| Year | Round | Amount | Valuation | % Sold |
|---|
Neurogene Employees & Team Size
We do not have information about Neurogene's team yet.
Founder / CEO
Q&A
| Question | Answer |
|---|---|
| What's your age? | - |
| Favorite online tool? | - |
| Favorite book? | - |
| Favorite CEO? | - |
| Advice for 20 year old self | - |
Customers
We do not have customer count information for Neurogene yet.
Frequently Asked Questions about Neurogene
What is Neurogene's revenue?
GetLatka has not confirmed a public revenue figure for Neurogene.
Who is the CEO of Neurogene?
The CEO of Neurogene is Rachel McMinn.
How much funding does Neurogene have?
Neurogene raised $0.
How many employees does Neurogene have?
Neurogene has 0 employees.
Where is Neurogene headquarters?
Neurogene is headquartered in New York, New York, United States.
Source Attribution
Source: all data was collected from GetLatka company research and founder interviews. Revenue, funding, team, and customer figures are presented as company-reported or GetLatka-estimated metrics where the profile data identifies them that way.
Company data last updated .